Abstract
Signal transducer and activator of transcription (STAT) proteins are second messengers in the JAK/STAT signaling pathway. The activation mechanism of STAT proteins involves phosphorylation on a single tyrosine residue by Janus-activated family kinases (JAK) in response to the binding of a series of extracellular proteins, such as cytokines, growth factors, hormones and membrane receptors. Activated via phosphorylation, STATs dissociate from the receptor, undergo dimerization and translocate to the nucleus, where they induce the transcription of target genes, commonly referred to as Interferon stimulated genes (ISGs). The family of STAT proteins has been documented to participate in normal cellular events, such as differentiation, proliferation, cell survival, apoptosis and angiogenesis. Constitutively activated STATs are involved in an aberrant signaling pathway which has transforming properties and occurs in cancer development. This review describes the mechanisms of JAK/STAT activation in normal and cancer cells. Moreover, it outlines the role of the JAK/STAT pathway in the inflammatory process as well as in oncogenesis. Additionally, the contribution of STAT and JAK proteins in molecular targeted cancer therapy is discussed.
Keywords: STAT proteins, JAK/STAT signaling pathway, inflammation, targeted therapy, cancer development, dimerization, phosphorylation, oligomerization, β-isoform, docking site
Current Signal Transduction Therapy
Title:Review: The JAK/STAT Protein Activation – Role in Cancer Development and Targeted Therapy
Volume: 7 Issue: 3
Author(s): Daria Domanska and Ewa Brzezianska
Affiliation:
Keywords: STAT proteins, JAK/STAT signaling pathway, inflammation, targeted therapy, cancer development, dimerization, phosphorylation, oligomerization, β-isoform, docking site
Abstract: Signal transducer and activator of transcription (STAT) proteins are second messengers in the JAK/STAT signaling pathway. The activation mechanism of STAT proteins involves phosphorylation on a single tyrosine residue by Janus-activated family kinases (JAK) in response to the binding of a series of extracellular proteins, such as cytokines, growth factors, hormones and membrane receptors. Activated via phosphorylation, STATs dissociate from the receptor, undergo dimerization and translocate to the nucleus, where they induce the transcription of target genes, commonly referred to as Interferon stimulated genes (ISGs). The family of STAT proteins has been documented to participate in normal cellular events, such as differentiation, proliferation, cell survival, apoptosis and angiogenesis. Constitutively activated STATs are involved in an aberrant signaling pathway which has transforming properties and occurs in cancer development. This review describes the mechanisms of JAK/STAT activation in normal and cancer cells. Moreover, it outlines the role of the JAK/STAT pathway in the inflammatory process as well as in oncogenesis. Additionally, the contribution of STAT and JAK proteins in molecular targeted cancer therapy is discussed.
Export Options
About this article
Cite this article as:
Domanska Daria and Brzezianska Ewa, Review: The JAK/STAT Protein Activation – Role in Cancer Development and Targeted Therapy, Current Signal Transduction Therapy 2012; 7 (3) . https://dx.doi.org/10.2174/157436212802481619
DOI https://dx.doi.org/10.2174/157436212802481619 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gap Junctions as Therapeutic Targets in Brain Injury Following Hypoxia- Ischemia
Recent Patents on CNS Drug Discovery (Discontinued) PDE5 Inhibitor Treatment Options for Urologic and Non-Urologic Indications: 2012 Update
Current Pharmaceutical Design The Epidemiology of Sepsis
Current Pharmaceutical Design A Comprehensive Review on Ethnomedicinal, Pharmacological and Phytochemical Basis of Anticancer Medicinal Plants of Pakistan
Current Cancer Drug Targets Exosome Limitations in the Treatment of Inflammatory Diseases
Current Pharmaceutical Design Anti-Cancer Agent-Induced Nephrotoxicity
Anti-Cancer Agents in Medicinal Chemistry Sorafenib (BAY 43-9006) in Hepatocellular Carcinoma Patients: From Discovery to Clinical Development
Current Medicinal Chemistry Outcome Measures Following Sonodynamic Photodynamic Therapy – A Case Series
Current Drug Therapy E2F1-Mediated Apoptosis as a Target of Cancer Therapy
Current Molecular Pharmacology Flavonoids as Sirtuin Modulators
Current Topics in Medicinal Chemistry Metastasis Suppressors: Basic and Translational Advances
Current Pharmaceutical Biotechnology Focus on the Multimodal Role of Biomarkers in Breast Cancer
Current Pharmaceutical Design Histone Lysine-Specific Methyltransferases and Demethylases in Carcinogenesis: New Targets for Cancer Therapy and Prevention
Current Cancer Drug Targets Titanocenes as Anticancer Agents: Recent Insights
Medicinal Chemistry p53 Peptide Prevents LITAF-Induced TNF-Alpha-Mediated Mouse Lung Lesions and Endotoxic Shock
Current Molecular Medicine Understanding Molecular Pathways and Targets of Brachyury in Epithelial-mesenchymal Transition (EMT) in Human Cancers
Current Cancer Drug Targets Carbonic Anhydrase Inhibitors Developed Through ‘Click Tailing’
Current Pharmaceutical Design Antitumor Titanium Compounds
Mini-Reviews in Medicinal Chemistry Targeting Protein Tyrosine Phosphatases for Anticancer Drug Discovery
Current Pharmaceutical Design Potassium Channels in Peripheral Pain Pathways: Expression, Function and Therapeutic Potential
Current Neuropharmacology